药物性牙龈肥大动物模型的建立及相关机制

doi:10.13591/j.cnki.kqyx.2022.10.014

摘要/Abstract

摘要： 药物性牙龈肥大是由钙通道阻滞剂、免疫抑制剂、抗癫痫药等引起的牙龈组织特异性肥大及纤维化。过去二十年间,学者从流行病学、临床试验、细胞学等层面对药物性牙龈肥大发生机制进行了大量研究。然而受限于临床患者数量及伦理问题,对其相关机制及治疗的深入研究依赖于动物实验。本文回顾了以往研究中药物性牙龈肥大动物模型的建立方法、相关机制及影响因素,以期为研究者建立可靠的动物模型提供参考。

关键词: 药物性牙龈肥大, 动物模型, 疾病模型

Abstract: Anti-seizure medication, calcium channel blocker and immune suppressor can cause gingival fibrosis and volume increase. In the past two decades, studies have explored the mechanism of drug-induced gingival overgrowth from aspects of epidemiology, clinical experiments and cytology. Subject to patient number and ethics, further investigation of mechanism and treatment relies on the establishment of animal model. This article reviews the research progress of animal model, relevant mechanism and influencing factors, in order to provide a reference for researchers to establish reliable animal models.

Key words: drug-induced gingiva enlargement, animal model, disease model

中图分类号:

R781.4

李佳博, 臧文丽, 潘亚萍. 药物性牙龈肥大动物模型的建立及相关机制[J]. 口腔医学, 2022, 42(10): 938-941.

LI Jiabo, ZANG Wenli, PAN Yaping. Establishment of animal model of drug-induced gingival enlargement and underlying mechanism[J]. Stomatology, 2022, 42(10): 938-941.

参考文献

[1] 孟焕新. 牙周病学[M]. 5版. 北京:人民卫生出版社, 2020:137-139.
[2] 李妍, 孟琛达, 徐全臣. 药物性牙龈肥大的病因研究及治疗进展[J]. 国际口腔医学杂志, 2020, 47(6):693-698.
[3] Morisaki I, Kato K, Loyola-Rodriguez JP, et al. Nifedipine-induced gingival overgrowth in the presence or absence of gingival inflammation in rats[J]. J Periodontal Res, 1993, 28(6 Pt 1):396-403.
[4] Ma S, Liu P, Li Y, et al. Cyclosporine ainhibitsapoptosis of rat gingival epithelium[J]. J Periodontol, 2014, 85(8):1126-1134.
[5] Adachi C, Kitamura K, Kato K, et al. Cyclosporin-A induced gingival overgrowth:Strain differences in the rats[J]. Shoni Shikagaku Zasshi, 1991, 29(1):24-31.
[6] Kanno CM, Oliveira JA, Ervolino E, et al. Effects of cyclosporin, nifedipine and phenytoin on gingival myofibroblast transdifferentiation in monkeys[J]. J Appl Oral Sci, 2018, 27:e20180135.
[7] Hassell TM, Roebuck S, Page RC, et al. Quantitative histopathologic assessment of developing phenytoin-induced gingival overgrowth in the cat[J]. J Clin Periodontol, 1982, 9(5):365-372.
[8] Heijl L, Sundin Y. Nitrendipine-induced gingival overgrowth in dogs[J]. J Periodontol, 1989, 60(2):104-112.
[9] Ishida H, Kondoh T, Kataoka M, et al. Factors influencing nifedipine-induced gingival overgrowth in rats[J]. JPeriodontol, 1995, 66(5):345-350.
[10] Morisaki I, Akiyama YM, Miyawaki YN, et al. Positive correlation between blood cyclosporin A level and severity of gingival overgrowth in rats[J]. J Periodontol, 1997, 68(1):7-11.
[11] Shimizu Y, Shinohara H, Nishikawa S, et al. Transglutaminase activity in rat gingival tissue[J]. Jpn Soc Periodontol, 1995,37:128.
[12] Nishikawa S, Nagata T, Morisaki I, et al. Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model[J]. J Periodontol, 1996, 67(5):463-471.
[13] Barak S, Engelberg IS, Hiss J. Gingival hyperplasia caused by nifedipine. Histopathologic findings[J]. J Periodontol, 1987, 58(9):639-642.
[14] Chang JH, Wang LF, Lu SL, et al. NF-κB enhances androgen receptor expression through 5'-UTR binding in gingival cells[J]. JDentRes, 2015, 94(10):1439-1445.
[15] Uzel MI,Kantarci A, Hong HH, et al. Connective tissue growth factor in drug-induced gingival overgrowth[J]. J Periodontol, 2001, 72(7):921-931.
[16] Anand AJ, Gopalakrishnan S, Karthikeyan R, et al. Immunohistochemical analysis of the role connective tissue growth factor in drug-induced gingival overgrowth in response to phenytoin, cyclosporine, and nifedipine[J]. J Int Soc Prev Community Dent, 2018, 8(1):12-20.
[17] 朱婷婷, 李楠楠, 陈志慧,等. 硝苯地平与环孢素A诱导的牙龈增生大鼠模型中血清TGF-β1的表达[J]. 牙体牙髓牙周病学杂志, 2018, 28(12):689-694.
[18] Yang F, Lu J, Yu Y, et al. Epithelial to mesenchymal transition in Cyclosporine A-induced rat gingival overgrowth[J]. Arch Oral Biol, 2017, 81:48-55.
[19] Tamamori Y, Tamura Y, Yamazaki T, et al. Establishment of rat model of drug-induced gingival overgrowth induced by continuous administration of phenytoin[J]. J Pharmacol Sci, 2005, 98(3):290-297.
[20] Assaggaf MA, Kantarci A, Sume SS, et al. Prevention of phenytoin-induced gingival overgrowth by lovastatin in mice[J]. AmJPathol, 2015, 185(6):1588-1599.
[21] Zhao XH, Tay FR, Fang YJ, et al. Topical application of phenytoin or nifedipine-loaded PLGA microspheres promotes periodontal regeneration in vivo[J]. Arch Oral Biol, 2019, 97:42-51.
[22] 谭葆春,闫福华.控制菌斑和炎症在牙龈肥大治疗中的效果评价[J].中华口腔医学杂志,2021,56(6):510-516.
[23] Migliozzi DR, Asal NJ. Clinical controversy in transplantation:Tacrolimus versus cyclosporine in statin drug interactions[J]. Ann Pharmacother, 2020, 54(2):171-177.
[24] Aícua-Rapún I, André P, Rossetti AO, et al. Therapeutic drug monitoring of newer antiepileptic drugs:A randomized trial for dosage adjustment[J]. Ann Neurol, 2020, 87(1):22-29.
[25] 国家卫生计生委合理用药专家委员会, 中国医师协会高血压专业委员会. 高血压合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版), 2017, 9(7):28-126.
[26] Fu E, Nieh S, Hsiao CT, et al. Nifedipine-induced gingival overgrowth in rats:Brief review and experimental study[J]. J Periodontol, 1998, 69(7):765-771.
[27] Okanobu A, Matsuda S, Kajiya M, et al. A novel gingival overgrowth mouse model induced by the combination of CsA and ligature-induced inflammation[J]. J Immunol Methods, 2017, 445:31-36.
[28] Matsuda S, Okanobu A, Hatano S, et al. Relationship between periodontal inflammation and calcium channel blockers induced gingival overgrowth-a cross-sectional study in a Japanese population[J]. Clin Oral Investig, 2019, 23(11):4099-4105.
[29] Li WL, Wu CH, Yang J, et al. Local inflammation alters MMP-2 and MMP-9 gelatinase expression associated with the severity of nifedipine-induced gingival overgrowth:Arat model study[J]. Inflammation, 2015, 38(4):1517-1528.
[30] Fernandes MI, Gaio EJ, Susin C, et al. Effect of nifedipine on gingival enlargement and periodontal breakdown in ligature-induced periodontitis in rats[J]. Arch Oral Biol, 2010, 55(7):523-529.
[31] Pamuk F, Cetinkaya BO, Gulbahar MY, et al. Effects of tacrolimus and nifedipine, alone or in combination, on gingival tissues[J]. J Periodontol, 2013, 84(11):1673-1682.
[32] Greenberg KV, Armitage GC, Shiboski CH. Gingival enlargement among renal transplant recipients in the era of new-generation immunosuppressants[J]. J Periodontol, 2008, 79(3):453-460.
[33] Fardal Ø, Lygre H. Management of periodontal disease in patients using calcium channel blockers-gingival overgrowth, prescribed medications, treatment responses and added treatment costs[J]. J Clin Periodontol, 2015, 42(7):640-646.
[34] Ma S, Liu W, Liu P, et al.Tanshinone IIA treatment alleviated the rat gingival connective tissue overgrowth induced by cyclosporine A[J]. J Periodontal Res, 2016, 51(5):567-576.
[35] Ju YQ, Huang LJ, Wang SW, et al. Transcriptional analysis reveals key genes in the pathogenesis of nifedipine-induced gingival overgrowth[J]. Anal Cell Pathol Amsterdam, 2020, 2020:6128341.
[36] Staudinger LA, Spano SJ, Lee WS, et al. Role of discoidin domain receptor 1 in dysregulation of collagen remodeling by cyclosporin A[J]. Int J Biochem Cell Biol, 2015, 62:80-87.
[37] Alshargabi R, Sano T, Yamashita A, et al. SPOCK₁ is a novel inducer of epithelial to mesenchymal transition in drug-induced gingival overgrowth[J]. Sci Rep, 2020, 10:9785.
[38] Yang Y, Huang X, Shi Y, et al. CYP3A5 genotype-dependent drug-drug interaction between tacrolimus and nifedipine in Chinese renal transplant patients[J]. Front Pharmacol, 2021, 12:692922.
[39] Hatano S, Matsuda S, Okanobu A, et al. The role of nuclear receptor 4A1 (NR4A1) in drug-induced gingival overgrowth[J]. FasebJ, 2021, 35(7):e21693.
[40] 段胜仲. 牙周微生态与心脑血管疾病研究进展[J]. 口腔医学, 2021, 41(7):577-582.